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Abstract: 
Introduction: Primary endocrine therapy (PET) is an alternative treatment to surgery for oestrogen 
receptor (ER) positive operable breast cancer in older women. However, there is variable use of PET 
in the UK, with up to 40% of patients aged over 70 receiving PET instead of surgery in some regions. 
Treatment options offered to patients rely heavily on healthcare professional (HCP) assessment and 
opinion on which treatments are appropriate. 
Materials and Methods: This was a mixed methods study combining semi-structured interviews with 
HCPs working in high and low PET regions in the UK, followed by a postal questionnaire survey 
distributed via the Association of Breast Surgery (ABS). 
Results: Thirty-four HCPs (20 breast surgeons; 13 nurse specialists; 1 geriatrician) were interviewed 
from 14 sites across the UK and 252/641 questionnaires returned (39%). There was an overriding 
view that PET is not suitable for patients under the age of 80 unless there are significant 
comorbidities. Opinion was split regarding the best way to treat patients with dementia. Patient 
preference was generally stated to be the most important factor when considering treatment, 
however only around a quarter 65/244 (26.6%) felt that all patients over the age of 70 should be 
offered PET as an alternative treatment option.  
Conclusions: Opinions differ on the best way to treat women over 70 with operable breast cancer, 
especially if they have co-existing dementia, as well as whether they should be offered PET as a 
treatment option. This may be a significant cause of treatment variation in the UK. 
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Introduction. 
One third of new breast cancer diagnoses occur in women aged over 70 years in the UK [1].. 
Increasing age results in rising rates of comorbidity and frailty [2] so tolerance to some standard 
breast cancer therapies may decrease [3] and older patients may prioritise quality of life over 
quantity [4]. Consequently, older patients with operable breast cancer may be offered alternative 
treatment modalities, such as primary endocrine therapy (PET) [5,6], where oestrogen receptor (ER) 
positive disease is treated with endocrine therapy alone. A meta-analysis comparing PET with 
surgery found no difference in survival, although rates of local control were inferior with PET [7], 
which may necessitate a change in management [8,9].  Case series indicate that older frailer women 
tend to be treated with PET and have inferior overall survival rates as would be expected due to 
higher other-cause mortality [10]. 
Significant cognitive impairment affects up to 20% of women aged between 80-84 years and is 
associated with a significant reduction in life expectancy [11]. Studies have shown that older women 
with dementia are less likely to receive surgical treatment for breast cancer [12]. Currently, there are 
no data on how this impacts on cancer outcomes in this group of women and therefore what best 
practice should be. 
National audits have demonstrated significant variation in the use of PET across the UK [13] which is 
not fully explained by case mix variation (stage, deprivation, etc.) [14]. Clinician preference has been 
suggested as a possible explanation for some of this variation [15]. To date, there is little in the 
published literature examining how healthcare professionals (HCPs) determine which older patients 
should be offered surgery, PET or a choice of both as treatment for operable breast cancer. This 
study aimed to determine what factors are important to HCPs when determining what treatment 
options to offer older patients with operable breast cancer and to explore their views and 
experience on the use of both surgery and PET in this population.   
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Materials and Methods:  
University of Sheffield Research Ethics Committee and local institutional approvals were obtained 
(SMBRER243). The study followed an exploratory sequential mixed methods design [16] (see figure 
1), using semi-structured qualitative interviews to initially explore and document the views and 
experiences of HCPs on the treatment of older women with operable breast cancer. The themes 
raised in these interviews then informed the development of a survey-style questionnaire to 
quantify the importance of these themes. 
Semi-structured Qualitative Interviews. 
Purposive sampling of HCPs (including breast surgeons, specialist nurses and geriatricians) from 
regions of high and low PET rates across the UK was performed. PET rates for each unit were derived 
from UK Registry data [13]. Semi-structured interviews were undertaken at the workplace of the 
individuals and written consent was obtained. Interviews were digitally recorded and transcribed 
verbatim. Recruitment ceased once data saturation had occurred. Analysis was performed using the 
National Centre for Social Research “Framework” approach to identify themes within the data [17].  
Quantitative Postal Questionnaire Survey. 
A postal questionnaire was designed based on the relevant literature and using the themes 
identified in the qualitative interviews, to maximise content validity. Face validity and acceptability 
were assessed during a pilot phase with 5 HCPs. The survey was mailed to all clinician and nurse 
members of the UK Association of Breast Surgery (ABS). An electronic reminder was sent via email to 
all members after four months. All analyses were performed using IBM SPSS Statistics version 21. 
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Results:  
Semi-structured Qualitative Interviews. 
Forty two HCPs were invited to interview and 34 agreed to be interviewed from 14 of the UK’s 166 
breast cancer units. Participants comprised of 20 surgeons (10 male, 10 female), 13 BCNs (all 
female), and 1 geriatrician (male). The mean duration of interviews was 33 minutes (16-55). Twenty-
one (62%) were from high PET units, with the remaining 13 from low PET units. There were no 
differences in characteristics between HCPs who took part and those that declined. 
Thematic analysis categorised data into three main themes summarising HCPs opinions on the use of 
surgery and PET in the management of older patients with operable breast cancer. These are 
summarised in Table 1 with representative quotes.   
 
Quantitative Postal Questionnaire Survey. 
Of the 641 questionnaires distributed, 251 were returned (39% response rate). See Table 2 for 
characteristics of respondents.  
 
Views of HCPs to treating older women with operable breast cancer. 
A key theme to emerge from the interviews was the importance of determining whether an older 
woman was fit for standard treatment i.e. surgery: 
“You’re trying to work out: are they fit enough” (Female nurse; high PET rate) 
Most said that age was not a factor when deciding treatment, and that other factors such as level of 
comorbidity, frailty and life expectancy, were more important. 
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“You give the patient treatment that the cancer deserves and not an age deserves… I would 
never differentiate on age because I wouldn't want that to be done to me and so why would I 
do it to someone else?” (Male surgeon; low PET rate) 
This seemed specifically to be the case when clinicians weighted various factors according to their 
importance (see Figure 2).  
Additionally, HCPs seemed to feel that the definition of “old” had increased: 
“I would say 70’s not really my cut off now, it’s more like 80… This kind of drive to do more 
surgery for elderly patients has actually raised the definition of ‘elderly’ from 70 to 80. I think 
we’re now dealing with the same questions but with a population of 10 years older” (Male 
surgeon; low PET rate) 
The presence of comorbidities was the most important factor when HCPs considered whether or not 
they determined an older woman to be fit for surgery with all respondents 248/248 (100%) rating 
this factor as having at least some importance (see Figure 2); and nearly two thirds (155/246; 63.0%) 
agreeing with the statement “All women ≥70 with operable ER+ breast cancer, who have multiple 
comorbidities such that anaesthesia may carry an increased risk of morbidity and mortality, should 
be treated with PET”.  
Significant dementia had a major impact on HCP treatment recommendations, with 102/248 (41.1%) 
agreeing with the statement “all women ≥70 with operable ER+ breast cancer, who have significant 
dementia (unable to give informed consent) should be treated with PET”.  In terms of relative 
importance, 89% rated the presence of dementia as very important or important in making 
treatment decisions. 
 
 
7 
 
Experience of surgical treatment in older women with breast cancer 
Surgery was generally considered to be the superior treatment option for older women with 
operable breast cancer:  
 “I’m of the opinion that surgery is the gold standard” (Female nurse; high PET rate) 
Over three quarters (199/249) of respondents agreed with the statement “All women ≥70 with 
operable breast cancer should be offered an operation regardless of age”. Furthermore 241/245 
(98.4%) of HCPs stated that in their experience, surgery under general anaesthetic (GA) was well 
tolerated in older women. However, experience with the usage of local anaesthetic (LA) and regional 
techniques was more variable, with only 43/244 (17.6%) stating that they had an anaesthetist who 
would happily perform regional blocks to allow surgical excision in patients where GA may carry an 
increased risk. Despite this, 156/244 (63.9%) felt that surgery under LA was well tolerated in older 
women and 148/246 (60.2%) agreed with the statement “surgery is almost always possible for older 
women ≥70 with operable breast cancer under local or regional anaesthesia”. 
Stage and size of the disease was viewed as being less important in determining treatment than 
patient health and fitness measures (see Figure 2) as although more than 87.4% (216/247) rated this 
as of at least some importance, only 22.7% (56/247) regarded it as very important.  Axillary disease 
was rated as slightly more important with 27.5% (68/247) rating it as very important. ER status was 
regarded as important or very important by most surgeons (216/248; 87.1%) but HER2 status much 
less so (123/245; 50.2%). 
Assessment of older patients for surgery also varied, with some HCPs using formal Comprehensive 
Geriatric Assessments (CGAs), others relying on their anaesthetic colleagues to guide them and 
many using simple assessments, such as whether the patients can walk up a flight of stairs, to 
determine their fitness (see table 1). 
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Experience of PET as a treatment in older women with breast cancer 
Primary Endocrine Therapy was generally regarded as the inferior treatment option by HCPs  
“Primary Endocrine Therapy alone probably long-term is not as good an option” (Female 
surgeon, high PET rate) 
With 65/244 (26.6%) agreeing that PET may be offered to any older woman with ER positive disease 
as there is no proven survival advantage. There was a strong view (217/247; 84.6%) that older 
women, if given the choice between PET or surgery, would choose surgery.   
Despite this, PET is still used to treat women across the UK, although its use is variable, with 17/240 
(7.1%) stating that more than 30% of women ≥70 were treated this way, 65/240 (27.1%) stating that 
20-30% of women ≥70 were treated with PET, 67/240 (27.9%) stating that 10-20% of women ≥70 
received PET and 91/240 (37.9%) stating that PET was used in less than 10% of women ≥70 years. 
There was variation regarding how long HCPs felt that PET was effective in maintaining local tumour 
control, with 64/238 (26.9%) stating 5 years or more; 74/238 (31.1%) stating 3 years, 70/238 (29.4%) 
stating 2 years and 30/238 (12.6%) stating 18 months or less.  
From the interviews, it was identified that most HCPs used aromatase inhibitors (AIs) as first line PET 
and this was usually Letrozole, although one commented that they used Tamoxifen and a couple 
used Anastrazole as first-line. Additionally, follow-up varied significantly between units (see table 1) 
and opinion was divided regarding what action to take if first-line anti-oestrogen failed to achieve a 
response, with 146/245 (59.6%) opting for a second-line anti-oestrogen, 61/245 (24.9%) advising 
operative management, 4/245 (1.6%) opting for radiotherapy and 34/245 (13.9%) stating that they 
would consider more than one of these options. 
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Discussion:  
The use of PET for the treatment of older breast cancer patients across the UK is variable [13] and 
this study supports these findings. Over a third of respondents stated they treated more than 20% of 
this population with PET, even though it was generally considered to be the inferior treatment 
option, with surgery as the ‘standard’.  
In 2008 the UK’s Department of Health established the National Cancer Equality Initiative (NCEI) 
aimed at lowering the inequality in cancer outcomes for all, including those of older patients [18]. 
Recent guidelines suggest that PET should only be offered to patients with a “short estimated life 
expectancy (<2-3 years), who are considered unfit for surgery… or who refuse surgery” [19]. 
However, they do not provide guidance regarding what constitutes being 'unfit' for surgery, and life 
expectancy is impossible to accurately assess with any certainty. As such it is left to the treating 
clinician to determine treatment, resulting in a wide variation in practice.  
Increasing age is associated with higher rates of comorbidity, which has been shown to potentially 
reduce the survival advantage of more aggressive breast cancer therapies [2]. Comorbidities are 
often stated as a reason for treating patients with PET [9, 20] and our results show that the presence 
of comorbidities was the most important factor HCPs considered when deciding treatment options 
for older patients with operable breast cancer. 
Life-expectancy was also considered relatively important however a recent UK questionnaire study 
found that surgeons are poor at gauging life-expectancy of older patients, with a tendency to under-
estimate it [20]. Older patients have a reduced life expectancy, with the average 75-year-old woman 
expected to life 13.5 years compared to 5.0 years for an average 90-year-old [21]. As such 
chronological age is often used by clinicians as a surrogate marker life expectancy and other factors, 
such as comorbidity and frailty [22].  
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Several studies have explored the issue of increasing age being associated with “under treatment” of 
older women with operable breast cancer [5, 23-25]. Our results show that whilst HCPs consider age 
one of the least important factors in determining which treatment options to offer, it remains 
important and several interview participants admitted to using age-specific cut-offs to determine 
who should be offered PET.  
Tumour factors were considered less important in treatment decision-making than patient factors, 
even though larger tumours are more likely to require mastectomy rather than breast conservation 
surgery. Nodal status was considered slightly more important and this may be due to the fact that 
surgery to clear the axilla under local anaesthesia is not technically possible and therefore surgery to 
clear an involved axilla would be precluded in women who were too frail to undergo GA. Despite the 
fact that HER2 positive cancers are known to be generally less likely to respond to endocrine therapy 
[26], it was considered much less important than ER status.   
There was a strong view that older women, if given the choice, would choose surgery over PET.  
Whether this statement’s response would have changed had the questionnaire contained a different 
age cut-off we are unable to confirm but current UK practice, combined with the findings that the 
definition of “old” has increased, would suggest this to be the case.   
This study identified major variation in the way PET is used in respect of the type of first-line anti-
oestrogen prescribed, the assessment methods and follow-up regimen used. This corroborates the 
findings by Wylie et al [20] and is most likely due to a lack of guidelines on its usage. A recent review 
on this subject advocates the use of AIs for PET, unless otherwise contraindicated [27] but there 
have been no studies that determine how best to follow these patients up. The involvement of 
geriatricians and the use of CGA in the assessment of older patients is also recommended [19], 
however few HCPs had access to this type of service. 
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The major drawback of PET is the risk of development of progressive disease which most patients 
will eventually suffer [28] although the length of time to progression varies greatly from nine to 132 
months [8, 29-32]. The duration of response is generally shorter in women who have only exhibited 
a partial response to PET, compared to those with a complete response [30, 33]. This may explain 
why there was so much variation in HCP opinion as to how long PET maintains tumour control. 
Evidence suggests that elderly patients may prioritise quality of life over quantity [4] and patient 
choice is commonly stated as a reason for treating patients with PET [10, 20]. However, a recent 
study by Lavelle and colleagues [23] found that lower rates of surgical treatment are unlikely to be 
due to patient choice and these results suggest that UK HCPs agree with this, believing that patients 
would not choose non-operative management if given the option. Hamaker and colleagues [15] 
suggested that variation in treatment may reflect underlying clinician preference influencing 
communication of treatment options. This seems a plausible explanation, especially in view of 
Schonberg and colleague’s findings that the most influential factor affecting older women’s breast 
cancer treatment decisions was the surgeon’s recommendation [34]. Indeed, this study 
demonstrates multiple areas of variation in HCP opinion supporting this.  
Around a quarter of HCPs agreed that PET may be offered to any older woman with ER positive 
disease as there is no proven survival advantage, which is more than three times the number found 
by Wylie et al [20]. Shared Decision-Making (SDM) suggests that patients should be informed of their 
treatment options [35]   and for some older women it may be appropriate to offer PET as an 
alternative to ‘standard’ surgical treatment and allow the patient to decide what is best for them. 
However, not all older patients engage in SDM, with many preferring a more passive role [34, 36-38], 
which may be reinforcing the variation due to clinician preferences.    
For those older breast cancer patients who are unable to make a decision due to significant 
dementia, opinion was divided regarding the best treatment approach. With dementia 
predominantly affecting the elderly, this represents a significant problem in this population. Studies 
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show that older patients with dementia are less likely to receive standard cancer therapies [12] and 
that this is often stated as a reason for selecting PET over surgery [6, 39]. However, there are 
currently no guidelines for the treatment of operable breast cancer in this complex group of patients 
which may reflect the lack of consensus amongst HCPs surveyed here. A further explanation for such 
differing views may be that dementia was not defined in the survey, and HCPs clinical judgement of 
dementia may vary in the absence of formal assessments. 
The use of local and regional anaesthesia for breast surgery in patients who are unable to undergo 
GA is well-established [40], with nearly two thirds of respondents feeling that surgery in older 
patients was well-tolerated under LA. However, it seems that a limiting factor in the utilisation of 
regional techniques is the availability of a suitably-experienced anaesthetist. 
Limitations of this study include the low response rate to the questionnaire, although this is 
comparable with other similar studies [20, 41], but limits the generalizability of the results. 
Additionally, it has previously been shown that most UK breast surgeons do not formally audit their 
practice in terms of PET [20] and so will have had to have estimated in some areas, such as the 
percentage of patients treated with PET. However the mixed methodology means that the 
questionnaire results complement and build on those from the interviews, giving a broader picture 
of this topic. 
In conclusion, HCP opinions differ on the best way to treat older women with operable breast 
cancer, especially if they have co-existing dementia, and whether they should be offered PET as a 
treatment option. This may be a significant cause of the variation in treatment of older women with 
breast cancer in the UK and highlights the urgent need for evidence based guidelines for decision 
making in this age group. 
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